Aarti Drugs Reports Mixed Q4 FY26 Results

Aarti Drugs Limited announced its financial results for the fourth quarter and full fiscal year ending March 31, 2026. The company posted revenue of ₹721.1 crore for Q4 FY26, a 6% increase from the same period last year and a 20% jump from the previous quarter. However, net profit declined by 12% year-over-year to ₹55.3 crore, though it was up 36% compared to the prior quarter. EBITDA for the quarter was ₹96.6 crore, remaining flat year-over-year but surging 72% quarter-over-quarter, with profit margins at 13.4%.

Navigating Industry Headwinds

Company officials noted that FY'26 was primarily an "execution year" focused on scaling operations. Aarti Drugs faced significant industry challenges, including geopolitical uncertainties, global trade disruptions, fluctuating input costs, and pricing volatility. Despite these pressures, the company made strategic progress on expanding its methylamines facility in Sayakha and advancing backward integration for metformin production. These initiatives are designed to enhance cost efficiencies and reduce reliance on imports.

Growth Drivers and Future Outlook

Aarti Drugs is prioritizing key growth areas to improve its financial performance. The methylamines plant at Sayakha is targeted to reach over 70% utilization within the next year, up from approximately 40% in Q4 FY26. Backward integration for metformin is also progressing, aimed at boosting cost competitiveness. The company anticipates an increase in exports to regulated markets. Management aims to maintain gross margins and projects FY27 EBITDA margins between 13.5% and 14%, a slight revision influenced by geopolitical factors.

Potential Risks

Several risks could impact Aarti Drugs' performance. The ongoing conflict in West Asia poses a threat to ammonia supply, and elevated input and freight costs persist. Fluctuations in crude oil prices may affect demand for certain older pharmaceutical molecules. The company is also addressing labor shortages and is seeking antidumping duties on salicylic acid. Ramp-up costs for the methylamine and salicylic acid projects are estimated to have resulted in an EBITDA loss of ₹18-20 crore for the fiscal year.

Strategic Position

Aarti Drugs operates in the competitive Active Pharmaceutical Ingredients (API) and formulations markets. Its strategy emphasizes expanding into regulated markets and pursuing backward integration to strengthen its market position against both domestic and international competitors. The company is also developing oncology formulations and expects equipment installation for its salicylic acid business.

Key Financials and Targets

• Q4 FY'26 Revenue: ₹721.1 crore (up 6% YoY, 20% QoQ).
• Q4 FY'26 EBITDA: ₹96.6 crore (flattish YoY, up 72% QoQ) at 13.4% margin.
• Q4 FY'26 Net Profit (PAT): ₹55.3 crore (down 12% YoY, up 36% QoQ) at 7.7% margin.
• Stand-alone Q4 FY'26 Revenue: ₹631.7 crore (up 0.8% YoY).
• FY'26 Formulation Revenue: ₹330.5 crore (up 16% YoY).
• FY'27 EBITDA Margin Target: 13.5% to 14%.
• Capital Expenditure: ₹300-400 crore planned over the next 2-3 years.

Looking Ahead

Investors will be closely monitoring the utilization rates of the methylamine plant, the success of the metformin backward integration, and the expansion of sales in regulated markets. The performance of the salicylic acid business and the impact of oncology formulation approvals will also be key. Achieving the targeted FY27 EBITDA margins amidst ongoing cost pressures remains a critical focus.